Payment overview · 2025
General Payments
$1,252.32
45 reported records · 11 companies
Healthcare provider profile · identity verified
Steve C Tam, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NEW YORK, NY · NPI 1285605394
Verified facts
What the public records show
CMS Open Payments records show Steve C Tam, MD received $1,252.32 in general payments during 2025 across 45 reported records.
Esperion Therapeutics, Inc. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Nexletol.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 403 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nexlizet by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $303.14 | 24.2% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $272.13 | 21.7% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $186.79 | 14.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $181.19 | 14.5% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.45 | 8.3% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $50.45 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.31 | 4.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.16 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.72 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.58 | 2.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.40 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,252.32 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $303.14 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $272.13 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $181.19 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $166.64 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $50.45 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.31 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $50.24 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $31.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $20.15 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 374 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 403 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
93 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
403 | 92 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
374 | 81 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
55 | 25 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
52 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
374 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1762 | 486 |
| Amlodipine Besylate | Amlodipine Besylate | 980 | 234 |
| Metoprolol Succinate | Metoprolol Succinate | 971 | 253 |
| Ezetimibe | Ezetimibe | 753 | 236 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 606 | 167 |
| Xarelto | Rivaroxaban | 523 | 119 |
| Losartan Potassium | Losartan Potassium | 496 | 124 |
| Jardiance | Empagliflozin | 403 | 92 |
| Vascepa | Icosapent Ethyl | 383 | 95 |
| Eliquis | Apixaban | 374 | 81 |
| Atenolol | Atenolol | 324 | 92 |
| Metformin Hcl | Metformin Hcl | 324 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 309 | 81 |
| Labetalol Hcl | Labetalol Hcl | 257 | 71 |
| Valsartan | Valsartan | 243 | 72 |
| Allopurinol | Allopurinol | 242 | 56 |
| Raloxifene Hcl | Raloxifene Hcl | 225 | 62 |
| Gabapentin | Gabapentin | 222 | 57 |
| Diclofenac Epolamine | Diclofenac Epolamine | 201 | 48 |
| Furosemide | Furosemide | 195 | 66 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 187 | 46 |
| Potassium Chloride | Potassium Chloride | 187 | 69 |
| Nebivolol Hcl | Nebivolol Hcl | 185 | 45 |
| Januvia | Sitagliptin Phosphate | 178 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 176 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 41 |
| Omeprazole | Omeprazole | 158 | 42 |
| Carvedilol | Carvedilol | 155 | 36 |
| Donepezil Hcl | Donepezil Hcl | 151 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 35 |
| Clobetasol Propionate | Clobetasol Propionate | 136 | 55 |
| Simvastatin | Simvastatin | 128 | 35 |
| Glimepiride | Glimepiride | 126 | 29 |
| Farxiga | Dapagliflozin Propanediol | 120 | 37 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 117 | 27 |
| Montelukast Sodium | Montelukast Sodium | 110 | 37 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 110 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 101 | 27 |
| Linzess | Linaclotide | 93 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 25 |
| Nifedipine Er | Nifedipine | 87 | 22 |
| Clonidine Hcl | Clonidine Hcl | 85 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 84 | 23 |
| Telmisartan | Telmisartan | 78 | 17 |
| Colchicine | Colchicine | 77 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 76 | 32 |
| Meclizine Hcl | Meclizine Hcl | 73 | 36 |
| Pregabalin | Pregabalin | 73 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 72 | 16 |
| Naproxen | Naproxen | 71 | 42 |
| Finasteride | Finasteride | 70 | 19 |
| Memantine Hcl | Memantine Hcl | 69 | 17 |
| Lidocaine | Lidocaine | 68 | 17 |
| Lorazepam | Lorazepam | 63 | 13 |
| Nitroglycerin | Nitroglycerin | 63 | 48 |
| Ammonium Lactate | Ammonium Lactate | 61 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 16 |
| Cilostazol | Cilostazol | 58 | 15 |
| Rybelsus | Semaglutide | 57 | 21 |
| Nexletol | Bempedoic Acid | 55 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 17 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 53 | 20 |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 52 | 32 |
| Tradjenta | Linagliptin | 52 | 16 |
| Warfarin Sodium | Warfarin Sodium | 52 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 11 |
| Ranolazine Er | Ranolazine | 48 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | 14 |
| Famotidine | Famotidine | 46 | 19 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 12 |
| Bepotastine Besilate | Bepotastine Besilate | 43 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 17 |
| Mometasone Furoate | Mometasone Furoate | 42 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 18 |
| Lisinopril | Lisinopril | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | 11 |
| Multaq | Dronedarone Hcl | 39 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | 15 |
| Nateglinide | Nateglinide | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 31 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Bystolic | Nebivolol Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 11 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Prolia | Denosumab | 21 | 14 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Nexium | Esomeprazole Magnesium | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 17 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Trulance | Plecanatide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | 12 |
| Nadolol | Nadolol | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,252.32 · 45 records | Esperion Therapeutics, Inc. | BREZTRI, CREON, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LOKELMA, NEXLETOL, REPATHA, VERQUVO, WATCHMAN Access System, WATCHMAN FLX, Wegovy | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error